---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-24-000297"
form_type: "8-K"
ticker: "BCRX"
cik: "0000882796"
company_name: "BIOCRYST PHARMACEUTICALS INC"
filed_at: "2024-01-18T23:59:59+00:00"
generated_at: "2026-06-06T22:20:10.184626+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.15
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# BioCryst adopts amended By-Laws for DGCL compliance and universal proxy card rules

## Summary
- Updates to align with DGCL Sections 219 and 222 regarding stockholder list and meeting adjournment.
- Revisions to stockholder nomination procedures to comply with universal proxy card rules (Rule 14a-19).
- Limits stockholder nominee count to number of directors to be elected; clarifies timing for substitute nominations.
- Requires soliciting stockholders to use a proxy card color other than white.
- Technical and administrative changes also adopted.

## SEC filing metadata
- accession: 0001171843-24-000297
- form_type: 8-K
- ticker: BCRX
- cik: 0000882796
- company_name: BIOCRYST PHARMACEUTICALS INC
- filed_at: 2024-01-18T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.15
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882796/000117184324000297/0001171843-24-000297-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882796/000117184324000297/f8k_011824.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-24-000297
- JSON: https://secwatch.observer/filing/0001171843-24-000297.json
- Plain text: https://secwatch.observer/filing/0001171843-24-000297.txt

## Key facts
- Governance Changes
  BIOCRYST PHARMACEUTICALS INC: Amended and Restated By-Laws effective January 16, 2024, including updates to align with Delaware law, revisions to stockholder meeting and nomination procedures, universal proxy rules, and technical changes (effective 2024-01-16).
  - Change: bylaw amendment
  - Effective: 2024-01-16
  source text: On January 16, 2024, the Board of Directors (the “Board”) of BioCryst Pharmaceuticals, Inc. (the “Company” or “BioCryst”) approved and adopted Amended and Restated By-Laws of the Company (as so amended and restated, the “By-Laws”), that became effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/882796/000117184324000297/0001171843-24-000297-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.